Research graph
References from Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases—A Systematic Review. Local targets link to admitted publications; unresolved targets remain external evidence.
Chimeric Antigen Receptor Therapy
10.1056/nejmra1706169 · 2018 · External reference
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
10.1056/nejmoa1804980 · 2019 · External reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · 2020 · External reference
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
10.1016/s0140-6736(21)01222-8 · 2021 · External reference
T cell circuits that sense antigen density with an ultrasensitive threshold
10.1126/science.abc1855 · 2021 · External reference
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
10.1126/science.aba1786 · 2021 · External reference
Engineering universal cells that evade immune detection
10.1038/s41577-019-0200-1 · 2019 · External reference
‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges
10.1038/s41573-019-0051-2 · 2020 · External reference
CAR T cells for infection, autoimmunity and allotransplantation
10.1038/s41577-018-0042-2 · 2018 · External reference
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
10.1126/science.aaf6756 · 2016 · External reference
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris
10.1172/jci138416 · 2020 · External reference
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
10.1038/s41591-022-02017-5 · 2022 · External reference
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
10.1126/scitranslmed.aav1648 · 2019 · External reference
Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus
10.1038/s41423-020-0472-1 · 2021 · External reference
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
10.1056/nejmc2107725 · 2021 · External reference
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
10.1016/j.ymthe.2016.12.023 · 2017 · External reference
10.1371/journal.ppat.1006613
10.1371/journal.ppat.1006613 · External reference
10.3390/v17121615
10.3390/v17121615 · External reference
Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model
10.1126/scitranslmed.aav5685 · 2019 · External reference
T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice
10.1053/j.gastro.2013.04.047 · 2013 · External reference
HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice
10.1016/j.jcyt.2018.02.002 · 2018 · External reference
Senolytic CAR T cells reverse senescence-associated pathologies
10.1038/s41586-020-2403-9 · 2020 · External reference
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
10.1056/nejmoa1914347 · 2020 · External reference
Non-viral chimeric antigen receptor (CAR) T cells going viral
10.1016/j.iotech.2023.100375 · 2023 · External reference
Transcriptional Regulation of Tissue-Resident Lymphocytes
10.1016/j.it.2016.11.004 · 2017 · External reference
Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: Peptide complex modulate the progression of autoimmune diabetes
10.1016/j.jaut.2018.08.004 · 2019 · External reference
10.3389/fimmu.2020.603237
10.3389/fimmu.2020.603237 · External reference
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
RoB 2: A revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
10.3390/publications14010004
10.3390/publications14010004 · External reference
Assessing the certainty of the evidence in systematic reviews: Importance, process, and use
10.1093/aje/kwae332 · 2025 · External reference
10.1371/journal.pone.0298526
10.1371/journal.pone.0298526 · External reference
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
10.1056/nejmc2509522 · 2025 · External reference
Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo
10.1038/s41591-020-1039-5 · 2020 · External reference
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
10.1186/1742-2094-9-112 · 2012 · External reference
Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes
10.1016/j.jaut.2019.05.017 · 2019 · External reference
Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes
10.1007/s00125-023-06076-2 · 2024 · External reference
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b/2a study
10.1016/s1474-4422(23)00194-1 · 2023 · External reference
CAR T cells produced in vivo to treat cardiac injury
10.1126/science.abm0594 · 2022 · External reference
Revolution in Cell Therapy: In Vivo Chimeric-Antigen-Receptor-T-Cell Therapy Breakthroughs and Promises for the Future
10.34133/research.0917 · 2025 · External reference
CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up
10.1056/nejmoa2308917 · 2024 · External reference
CD19-targeted CAR T cells in refractory antisynthetase syndrome
10.1016/s0140-6736(23)00023-5 · 2023 · External reference
Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis
10.1136/ard-2024-226017 · 2024 · External reference
Targeting autoimmunity with CD19-CAR T-cell therapy: Efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis
10.1093/rheumatology/keaf077 · 2025 · External reference
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells
10.1136/ard-2023-223952 · 2023 · External reference
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
10.1001/jama.2023.8753 · 2023 · External reference
Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies
10.1093/rheumatology/kead330 · 2024 · External reference
10.1371/journal.ppat.1006753
10.1371/journal.ppat.1006753 · External reference
10.1371/journal.ppat.1002649
10.1371/journal.ppat.1002649 · External reference
HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies
10.1128/jvi.00805-16 · 2016 · External reference
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
10.1016/j.cell.2019.10.002 · 2019 · External reference
Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection
10.1126/science.1256304 · 2014 · External reference
Allogeneic CAR T cell therapies for leukemia
10.1002/ajh.25399 · 2019 · External reference
T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes
10.1053/j.gastro.2007.11.002 · 2008 · External reference
Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
10.1136/gutjnl-2018-316510 · 2018 · External reference
CAR-T cells shed light on the treatments of fatal liver diseases
10.21037/biotarget.2018.02.01 · 2018 · External reference
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases
10.1016/j.jhep.2025.06.007 · 2025 · External reference
Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
10.1136/gutjnl-2014-308316 · 2015 · External reference
Chimeric antigen receptor T-cell therapy in chronic viral infections: A review
10.1186/s12967-025-07582-0 · 2026 · External reference
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
10.1016/s0140-6736(03)14634-x · 2003 · External reference
Adoptive Immunotherapy With CMV-specific Cytotoxic T Lymphocytes for Stem Cell Transplant Patients With Refractory CMV Infections
10.1097/cji.0b013e31824300a2 · 2012 · External reference
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
10.1182/blood-2009-08-239186 · 2010 · External reference
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
10.1172/jci121127 · 2019 · External reference
10.3389/fimmu.2024.1437901
10.3389/fimmu.2024.1437901 · External reference
Cytotoxic granules and effector molecules from immune cells in tuberculosis: Mechanisms of host defense and therapeutic potential
10.1080/21505594.2025.2542466 · 2025 · External reference
Programmed death-1 receptor suppresses γ-IFN producing NKT cells in human tuberculosis
10.1016/j.tube.2014.01.005 · 2014 · External reference
Unresolved reference
External reference
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
10.1056/nejmoa1708566 · 2017 · External reference
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
10.1016/j.bbmt.2018.12.758 · 2019 · External reference
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
10.1038/s41591-019-0472-9 · 2019 · External reference
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: A phase 1 trial
10.1038/s41591-025-03899-x · 2025 · External reference
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
10.1001/jama.2023.8753 · ExternalCitation · doi-reference
Allogeneic CAR T cell therapies for leukemia
10.1002/ajh.25399 · ExternalCitation · doi-reference
Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes
10.1007/s00125-023-06076-2 · ExternalCitation · doi-reference
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
10.1016/j.bbmt.2018.12.758 · ExternalCitation · doi-reference
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
10.1016/j.cell.2019.10.002 · ExternalCitation · doi-reference
Non-viral chimeric antigen receptor (CAR) T cells going viral
10.1016/j.iotech.2023.100375 · ExternalCitation · doi-reference
Transcriptional Regulation of Tissue-Resident Lymphocytes
10.1016/j.it.2016.11.004 · ExternalCitation · doi-reference
Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: Peptide complex modulate the progression of autoimmune diabetes
10.1016/j.jaut.2018.08.004 · ExternalCitation · doi-reference
Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes
10.1016/j.jaut.2019.05.017 · ExternalCitation · doi-reference
HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice
10.1016/j.jcyt.2018.02.002 · ExternalCitation · doi-reference
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases
10.1016/j.jhep.2025.06.007 · ExternalCitation · doi-reference
Programmed death-1 receptor suppresses γ-IFN producing NKT cells in human tuberculosis
10.1016/j.tube.2014.01.005 · ExternalCitation · doi-reference
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
10.1016/j.ymthe.2016.12.023 · ExternalCitation · doi-reference
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
10.1016/s0140-6736(03)14634-x · ExternalCitation · doi-reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · ExternalCitation · doi-reference
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
10.1016/s0140-6736(21)01222-8 · ExternalCitation · doi-reference
CD19-targeted CAR T cells in refractory antisynthetase syndrome
10.1016/s0140-6736(23)00023-5 · ExternalCitation · doi-reference
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b/2a study
10.1016/s1474-4422(23)00194-1 · ExternalCitation · doi-reference
Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus
10.1038/s41423-020-0472-1 · ExternalCitation · doi-reference
‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges
10.1038/s41573-019-0051-2 · ExternalCitation · doi-reference
CAR T cells for infection, autoimmunity and allotransplantation
10.1038/s41577-018-0042-2 · ExternalCitation · doi-reference
Engineering universal cells that evade immune detection
10.1038/s41577-019-0200-1 · ExternalCitation · doi-reference
Senolytic CAR T cells reverse senescence-associated pathologies
10.1038/s41586-020-2403-9 · ExternalCitation · doi-reference
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
10.1038/s41591-019-0472-9 · ExternalCitation · doi-reference
Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo
10.1038/s41591-020-1039-5 · ExternalCitation · doi-reference
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
10.1038/s41591-022-02017-5 · ExternalCitation · doi-reference
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: A phase 1 trial
10.1038/s41591-025-03899-x · ExternalCitation · doi-reference
T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes
10.1053/j.gastro.2007.11.002 · ExternalCitation · doi-reference
T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice
10.1053/j.gastro.2013.04.047 · ExternalCitation · doi-reference
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
10.1056/nejmc2107725 · ExternalCitation · doi-reference
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
10.1056/nejmc2509522 · ExternalCitation · doi-reference
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
10.1056/nejmoa1707447 · ExternalCitation · doi-reference
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
10.1056/nejmoa1708566 · ExternalCitation · doi-reference
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
10.1056/nejmoa1804980 · ExternalCitation · doi-reference
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
10.1056/nejmoa1914347 · ExternalCitation · doi-reference
CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up
10.1056/nejmoa2308917 · ExternalCitation · doi-reference
Chimeric Antigen Receptor Therapy
10.1056/nejmra1706169 · ExternalCitation · doi-reference
Cytotoxic granules and effector molecules from immune cells in tuberculosis: Mechanisms of host defense and therapeutic potential
10.1080/21505594.2025.2542466 · ExternalCitation · doi-reference
Assessing the certainty of the evidence in systematic reviews: Importance, process, and use
10.1093/aje/kwae332 · ExternalCitation · doi-reference
Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies
10.1093/rheumatology/kead330 · ExternalCitation · doi-reference
Targeting autoimmunity with CD19-CAR T-cell therapy: Efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis
10.1093/rheumatology/keaf077 · ExternalCitation · doi-reference
Adoptive Immunotherapy With CMV-specific Cytotoxic T Lymphocytes for Stem Cell Transplant Patients With Refractory CMV Infections
10.1097/cji.0b013e31824300a2 · ExternalCitation · doi-reference
Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection
10.1126/science.1256304 · ExternalCitation · doi-reference
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
10.1126/science.aaf6756 · ExternalCitation · doi-reference
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
10.1126/science.aba1786 · ExternalCitation · doi-reference
T cell circuits that sense antigen density with an ultrasensitive threshold
10.1126/science.abc1855 · ExternalCitation · doi-reference
CAR T cells produced in vivo to treat cardiac injury
10.1126/science.abm0594 · ExternalCitation · doi-reference
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
10.1126/scitranslmed.aav1648 · ExternalCitation · doi-reference
Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model
10.1126/scitranslmed.aav5685 · ExternalCitation · doi-reference
HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies
10.1128/jvi.00805-16 · ExternalCitation · doi-reference
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells
10.1136/ard-2023-223952 · ExternalCitation · doi-reference
Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis
10.1136/ard-2024-226017 · ExternalCitation · doi-reference
RoB 2: A revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · ExternalCitation · doi-reference
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
10.1136/bmj.n71 · ExternalCitation · doi-reference
Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
10.1136/gutjnl-2014-308316 · ExternalCitation · doi-reference
Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
10.1136/gutjnl-2018-316510 · ExternalCitation · doi-reference
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
10.1172/jci121127 · ExternalCitation · doi-reference
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris
10.1172/jci138416 · ExternalCitation · doi-reference
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
10.1182/blood-2009-08-239186 · ExternalCitation · doi-reference
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
10.1186/1742-2094-9-112 · ExternalCitation · doi-reference
Chimeric antigen receptor T-cell therapy in chronic viral infections: A review
10.1186/s12967-025-07582-0 · ExternalCitation · doi-reference
10.1371/journal.pone.0298526
10.1371/journal.pone.0298526 · ExternalCitation · doi-reference
10.1371/journal.ppat.1002649
10.1371/journal.ppat.1002649 · ExternalCitation · doi-reference
10.1371/journal.ppat.1006613
10.1371/journal.ppat.1006613 · ExternalCitation · doi-reference
10.1371/journal.ppat.1006753
10.1371/journal.ppat.1006753 · ExternalCitation · doi-reference
CAR-T cells shed light on the treatments of fatal liver diseases
10.21037/biotarget.2018.02.01 · ExternalCitation · doi-reference
10.3389/fimmu.2020.603237
10.3389/fimmu.2020.603237 · ExternalCitation · doi-reference
10.3389/fimmu.2024.1437901
10.3389/fimmu.2024.1437901 · ExternalCitation · doi-reference
10.3390/publications14010004
10.3390/publications14010004 · ExternalCitation · doi-reference
10.3390/v17121615
10.3390/v17121615 · ExternalCitation · doi-reference
Revolution in Cell Therapy: In Vivo Chimeric-Antigen-Receptor-T-Cell Therapy Breakthroughs and Promises for the Future
10.34133/research.0917 · ExternalCitation · doi-reference
